keyword
https://read.qxmd.com/read/38492622/targeting-inflammatory-signaling-pathways-with-sglt2-inhibitors-insights-into-cardiovascular-health-and-cardiac-cell-improvement
#21
REVIEW
Fatmah R Alsereidi, Zenith Khashim, Hezlin Marzook, Anamika Gupta, Ahmed M Shaaban, Mahmoud M Ramadan, Mohamed A Saleh
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have attracted significant attention for their broader therapeutic impact beyond simply controlling blood sugar levels, particularly in their ability to influence inflammatory pathways. This review delves into the anti-inflammatory properties of SGLT2 inhibitors, with a specific focus on canagliflozin, empagliflozin, and dapagliflozin. One of the key mechanisms through which SGLT2 inhibitors exert their anti-inflammatory effects is by activating AMP-activated protein kinase (AMPK), a crucial regulator of both cellular energy balance and inflammation...
March 14, 2024: Current Problems in Cardiology
https://read.qxmd.com/read/38488029/role-and-molecular-mechanisms-of-sglt2-inhibitors-in-pathological-cardiac-remodeling-review
#22
REVIEW
Bixian Chen, Jing Guo, Hongmei Ye, Xinyu Wang, Yufei Feng
Cardiovascular diseases are caused by pathological cardiac remodeling, which involves fibrosis, inflammation and cell dysfunction. This includes autophagy, apoptosis, oxidative stress, mitochondrial dysfunction, changes in energy metabolism, angiogenesis and dysregulation of signaling pathways. These changes in heart structure and/or function ultimately result in heart failure. In an effort to prevent this, multiple cardiovascular outcome trials have demonstrated the cardiac benefits of sodium‑glucose cotransporter type 2 inhibitors (SGLT2is), hypoglycemic drugs initially designed to treat type 2 diabetes mellitus...
May 2024: Molecular Medicine Reports
https://read.qxmd.com/read/38484937/effect-of-sodium-glucose-cotransporter-2-inhibitors-on-24-hour-ambulatory-blood-pressure-in-patients-with-type-2-diabetes-and-hypertension-an-updated-meta-analysis
#23
REVIEW
Fizza Iqbal, Muhammad Hamza Shuja, Laraib Azam, Marium Amjad, Kashish Zehra Manjee, Hurriyah Ramzan, Taha Sharif, Ayesha Shoaib, Amber Tahir, Satesh Kumar, Mahima Khatri, Giustino Varrassi, Tamam Mohamad
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for type 2 diabetes treatment, have shown potential benefits beyond glycemic control, including a positive impact on blood pressure. This meta-analysis aims to evaluate their effects on patients with type 2 diabetes and hypertension. METHODS: We searched PubMed, Google Scholar, and Cochrane databases for relevant randomized controlled trials (RCTs) published until May 31, 2023. Ten RCTs involving participants with confirmed Type 2 diabetes mellitus were selected...
March 12, 2024: Endocrine Practice
https://read.qxmd.com/read/38484469/protecting-cardiomyocytes-from-hypoxia-reoxygenation-injury-empaglifozin-and-liraglutide-alone-or-in-combination
#24
JOURNAL ARTICLE
Francesca Amici, Christian Ciarlo, Jenine Abumusallam, Madeline Kravitz, Angel-Rose Weber, Hanna Meister, Zhao Li
OBJECTIVES: Empagliflozin, a sodium-dependent glucose co-transporter 2 (SGLT2) inhibitor, and liraglutide, a GLP-1 receptor (GLP-1R) agonist, are commonly recognized for their cardiovascular benefits in individuals with type 2 diabetes (T2D). In prior studies, we have demonstrated that both drugs, alone or in combination, were able to protect cardiomyocytes from injury induced by diabetes. Mechanistic investigations also suggested that the cardioprotective effect may be independent of diabetes In this study, we utilized a hypoxia-reoxygenation (H/R) model to investigate the cardiovascular benefits of SGLT2 inhibitor empagliflozin and GLP-1 receptor (GLP-1R) agonist liraglutide, both alone and in combination, in the absence of T2D...
March 15, 2024: Journal of Basic and Clinical Physiology and Pharmacology
https://read.qxmd.com/read/38484180/association-between-sodium-glucose-cotransporter-2-inhibitors-and-arrhythmic-outcomes-in-patients-with-diabetes-and-pre-existing-atrial-fibrillation
#25
JOURNAL ARTICLE
Akash Fichadiya, Amity Quinn, Flora Au, Dennis Campbell, Darren Lau, Paul Ronksley, Reed Beall, David J T Campbell, Stephen B Wilton, Derek S Chew
AIMS: Prior studies suggest that sodium-glucose cotransporter-2 inhibitors (SGLT2is) may decrease the incidence of atrial fibrillation (AF). However, it is unknown whether SGLT2i can attenuate the disease course of AF among patients with pre-existing AF and Type II diabetes mellitus (DM). In this study, our objective was to examine the association between SGLT2i prescription and arrhythmic outcomes among patients with DM and pre-existing AF. METHODS AND RESULTS: We conducted a population-based cohort study of adults with DM and AF between 2014 and 2019...
March 1, 2024: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://read.qxmd.com/read/38478491/cost-effectiveness-of-screening-for-chronic-kidney-disease-using-a-cumulative-egfr-based-statistic
#26
JOURNAL ARTICLE
Reyhaneh Zafarnejad, Qiushi Chen, Paul M Griffin
OBJECTIVES: Routine screening for chronic kidney disease (CKD) could enable timely interventions to slow down disease progression, but currently there are no clinical guidelines for screening. We aim to evaluate the cost-effectiveness of screening for CKD using a novel analytical tool based on a cumulative sum statistic of estimated glomerular filtration rate (CUSUMGFR). METHODS: We developed a microsimulation model that captured CKD disease progression, major complications, patients' awareness, and treatment adherence for a nationally representative synthetic cohort of age ≥ 30 years in the United States...
2024: PloS One
https://read.qxmd.com/read/38477973/implementing-a-sodium-glucose-cotransporter-2-inhibitor-module-with-a-software-tool-future-health-today-qualitative-study
#27
JOURNAL ARTICLE
Matthew Suen, Jo-Anne Manski-Nankervis, Caroline McBride, Natalie Lumsden, Barbara Hunter
BACKGROUND: Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management...
March 13, 2024: JMIR Formative Research
https://read.qxmd.com/read/38475903/effects-of-empagliflozin-induced-glycosuria-on-weight-gain-food-intake-and-metabolic-indicators-in-mice-fed-a-high-fat-diet
#28
JOURNAL ARTICLE
Anh T Nguyen, Zachary Amigo, Kathleen McDuffie, Victoria C MacQueen, Lane D Bell, Lan K Truong, Gloria Batchi, Sara M McMillin
BACKGROUND: Sodium glucose-linked transporter 2 (SGLT2) inhibitors promote glucose, and therefore calorie, excretion in the urine. Patients taking SGLT2 inhibitors typically experience mild weight loss, but the amount of weight loss falls short of what is expected based on caloric loss. Understanding the mechanisms responsible for this weight loss discrepancy is imperative, as strategies to improve weight loss could markedly improve type 2 diabetes management and overall metabolic health...
March 2024: Endocrinology, Diabetes & Metabolism
https://read.qxmd.com/read/38472344/the-clinical-benefits-of-sodium-glucose-cotransporter-type-2-inhibitors-in-people-with-gout
#29
REVIEW
Chio Yokose, Natalie McCormick, Abhishek Abhishek, Nicola Dalbeth, Tristan Pascart, Frédéric Lioté, Angelo Gaffo, John FitzGerald, Robert Terkeltaub, Meghan E Sise, James L Januzzi, Deborah J Wexler, Hyon K Choi
Gout is the most common form of inflammatory arthritis worldwide and is characterized by painful recurrent flares of inflammatory arthritis that are associated with a transiently increased risk of adverse cardiovascular events. Furthermore, gout is associated with multiple cardiometabolic-renal comorbidities such as type 2 diabetes, chronic kidney disease and cardiovascular disease. These comorbidities, potentially combined with gout flare-related inflammation, contribute to persistent premature mortality in gout, independently of serum urate concentrations and traditional cardiovascular risk factors...
March 12, 2024: Nature Reviews. Rheumatology
https://read.qxmd.com/read/38471012/gut-microbiota-tryptophan-metabolism-glp-1-axis-participates-in-%C3%AE-cell-regeneration-induced-by-dapagliflozin
#30
JOURNAL ARTICLE
Yafei Jiang, Jin Yang, Li Xia, Tianjiao Wei, Xiaona Cui, Dandan Wang, Zirun Jin, Xiafang Lin, Fei Li, Kun Yang, Shan Lang, Ye Liu, Jing Hang, Zhe Zhang, Tianpei Hong, Rui Wei
Sodium-glucose co-transporter 2 (SGLT2) inhibitor, an efficacious anti-diabetic agent, which has cardiovascular and renal benefits, can promote pancreatic β-cell regeneration in type 2 diabetic mice. However, the underlying mechanism remains unclear. In this study, we aimed to use multi-omics to identify the mediators involved in β-cell regeneration induced by dapagliflozin. We showed that dapagliflozin lowered blood glucose level, upregulated plasma insulin level, and increased islet area in db/db mice...
March 12, 2024: Diabetes
https://read.qxmd.com/read/38466894/sglt2-inhibitors-vs-glp-1-receptor-agonists-and-clinical-outcomes-in-patients-with-diabetes-with-without-atrial-fibrillation
#31
JOURNAL ARTICLE
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y H Lip
CONTEXT: The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with substantial risks of adverse cardiovascular events. OBJECTIVE: The relevant outcomes associated with the use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP-1RA) among patients with type 2 diabetes (T2D) with/without concomitant AF remained unknown. METHODS: In this nationwide retrospective cohort study from Taiwan National Health Insurance Research Database, there were 344,392 and 31,351 patients with T2D without AF, and 11,462 and 816 T2D patients with AF treated with SGLT2i and GLP-1RA from May 1, 2016, to December 31, 2019...
March 11, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38466796/inhibition-of-sodium-glucose-cotransporter-2-and-liver-related-complications-in-individuals-with-diabetes-a-mendelian-randomization-and-population-based-cohort-study
#32
JOURNAL ARTICLE
Sung Won Chung, Hye-Sung Moon, Hyunjae Shin, Hyein Han, Sehoon Park, Heejin Cho, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Sung-Ho Won, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Ki Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Yoon Jun Kim
BACKGROUND AIMS: No medication has been found to reduce the liver-related events. We evaluated the effect of sodium-glucose cotransporter-2 inhibitor (SGLT2i) on liver-related outcomes. APPROACH RESULTS: Single nucleotide polymorphisms (SNPs) associated with SGLT2 inhibition were identified, and a genetic risk score (GRS) was computed using the UK Biobank (UKB) data (n=337,138). Two-sample Mendelian randomization (MR) was conducted using the FinnGen (n=218,792) database and UKB data...
March 11, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38465737/solution-is-not-simple-sodium-glucose-cotransporter-2-inhibitor-use-in-conn-syndrome
#33
JOURNAL ARTICLE
Utku Soyaltin
PURPOSE: In patients with bilateral primary hyperaldosteronism (PA) and those with unilateral PA who are unwilling or unable to undergo adrenalectomy an increase in plasma renin activity (PRA) provided by mineralocorticoid receptor antagonists (MRAs) therapy reflects sufficient antagonism for elevated aldosterone. Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) have cardiovascular, renal protective properties and some clinical data have shown an increase in PRA levels with SGLT2-i...
March 11, 2024: Blood Pressure Monitoring
https://read.qxmd.com/read/38465470/lessons-learned-from-early-stage-clinical-trials-for-diabetic-nephropathy
#34
JOURNAL ARTICLE
Marc Rendell
INTRODUCTION: The evolution of treatment for diabetic nephropathy illustrates how basic biochemistry and physiology have led to new agents such as SGLT2 inhibitors and mineralocorticoid blockers. Conversely, clinical studies performed with these agents have suggested new concepts for investigational drug development. We reviewed currently available treatments for diabetic nephropathy and then analyzed early clinical trials of new agents to assess potential for future treatment modalities...
March 11, 2024: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/38465348/drug-safety-evaluation-of-sodium-glucose-cotransporter-2-inhibitors-in-diabetic-comorbid-patients-by-review-of-systemic-extraglycemic-effects
#35
REVIEW
Mohammad Belal Omari, Shafiqullah Naseri, Abdul Jalil Hassan
PURPOSE: The aim of this study is to evaluate the safety of this drug in diabetic patients with comorbidities of all systems. METHOD: In this review, the beneficial effects of this drug and its mechanism on the disorders of every system of humans in relation to diabetes have been studied, and finally, its adverse effects have also been discussed. The search for relevant information is carried out in the PubMed and Google Scholar databases by using the following terms: diabetes mellitus type 2, SGLT, SGLT2 inhibitors, (SGLT2 inhibitors) AND (Pleiotropic effects)...
2024: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/38464375/elucidating-the-cardioprotective-mechanisms-of-sodium-glucose-cotransporter-2-inhibitors-beyond-glycemic-control
#36
EDITORIAL
Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a pivotal intervention in diabetes management, offering significant cardiovascular benefits. Empagliflozin, in particular, has demonstrated cardioprotective effects beyond its glucose-lowering action, reducing heart failure hospitalizations and improving cardiac function. Of note, the cardioprotective mechanisms appear to be inde-pendent of glucose lowering, possibly mediated through several mechanisms involving shifts in cardiac metabolism and anti-fibrotic, anti-inflammatory, and anti-oxidative pathways...
February 15, 2024: World Journal of Diabetes
https://read.qxmd.com/read/38459768/effect-of-sodium-glucose-cotransporter%C3%A2-2-inhibitors-on-serum-low-density-lipoprotein-cholesterol-in-japanese-patients-with-type%C3%A2-2-diabetes-mellitus
#37
JOURNAL ARTICLE
Tasuku Imada, Naoto Katakami, Hirotaka Watanabe, Shuhei Nishina, Shugo Sasaki, Mitsuyoshi Takahara, Iichiro Shimomura, Tsunehiko Yamamoto
AIMS/INTRODUCTION: We aimed to evaluate factors that influence changes in blood low-density lipoprotein cholesterol (LDL-C) levels after treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors in Japanese patients with type 2 diabetes. MATERIALS AND METHODS: We retrospectively analyzed clinical data of outpatients newly initiated on SGLT2 inhibitors (n = 176) and other oral antidiabetic drugs (n = 227). The patients were classified into four subgroups according to statin administration and baseline LDL-C levels (<120 or ≥120 mg/dL)...
March 8, 2024: Journal of Diabetes Investigation
https://read.qxmd.com/read/38458647/glp-1-receptor-agonists-in-the-treatment-of-diabetic-non-alcoholic-steatohepatitis-patients
#38
JOURNAL ARTICLE
Ernest A Adeghate
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease affecting almost 30% of the world population. Approximately 25% of people with NAFLD develop nonalcoholic steatohepatitis (NASH), the fulminant version of the disease. Diabetes mellitus is present in 22.5% of people with NAFLD and 44.60% of individuals with NASH. This review was undertaken to examine the current contribution of glucagon-like peptide 1 (GLP-1) receptor agonists to the pharmacotherapy of diabetic nonalcoholic steatohepatitis...
March 8, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38456717/early-sglt2-inhibitor-use-is-associated-with-improved-left-atrial-strain-following-acute-coronary-syndrome
#39
JOURNAL ARTICLE
Amro Sehly, Albert He, Abdul Rahman Ihdayhid, Christine Grey, Scott O'Connor, Gillian Green, Matthew Erickson, James M Rankin, P Gerry Fegan, Bu B Yeap, Girish Dwivedi, Nick S R Lan
AIM: Left atrial (LA) strain, a novel marker of LA function, reliably predicts diastolic dysfunction. SGLT2 inhibitors improve heart failure outcomes, but limited data exists regarding their use in the immediate aftermath of acute coronary syndrome (ACS). We studied the effect of empagliflozin on LA strain in patients with type 2 diabetes (T2D) and ACS. METHODS: Patients with ACS and T2D were identified and empagliflozin was initiated in eligible patients prior to discharge...
March 8, 2024: Acta Cardiologica
https://read.qxmd.com/read/38456601/sglt2-inhibitors-from-glucose-lowering-to-cardiovascular-benefits
#40
JOURNAL ARTICLE
Alberto Preda, Fabrizio Montecucco, Federico Carbone, Giovanni G Camici, Thomas F Lüscher, Simon Kraler, Luca Liberale
An increasing number of individuals is at high risk of type 2 diabetes (T2D) and its cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD), and premature death. The sodium-glucose cotransporter-2 (SGLT2) protein sits in the proximal tubule of human nephrons to regulate glucose reabsorption, and its inhibition by gliflozins represents the cornerstone of contemporary T2D and HF management. Herein, we aim to provide an updated view on the pleiotropy of gliflozins, provide mechanistic insights and delineate related cardiovascular (CV) benefits...
March 8, 2024: Cardiovascular Research
keyword
keyword
167864
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.